The Complement System in Kidney Transplantation

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Mar 11

PMID 36899927

Authors

Donata Santarsiero

Sistiana Aiello

Affiliations

Soon will be listed here.

Abstract

Kidney transplantation is the therapy of choice for patients who suffer from end-stage renal diseases. Despite improvements in surgical techniques and immunosuppressive treatments, long-term graft survival remains a challenge. A large body of evidence documented that the complement cascade, a part of the innate immune system, plays a crucial role in the deleterious inflammatory reactions that occur during the transplantation process, such as brain or cardiac death of the donor and ischaemia/reperfusion injury. In addition, the complement system also modulates the responses of T cells and B cells to alloantigens, thus playing a crucial role in cellular as well as humoral responses to the allograft, which lead to damage to the transplanted kidney. Since several drugs that are capable of inhibiting complement activation at various stages of the complement cascade are emerging and being developed, we will discuss how these novel therapies could have potential applications in ameliorating outcomes in kidney transplantations by preventing the deleterious effects of ischaemia/reperfusion injury, modulating the adaptive immune response, and treating antibody-mediated rejection.

Citing Articles

Comprehensive profiling of cell type-specific expression and distribution of complement genes in mouse and human kidneys: insights into normal physiology and response to kidney transplantations.

Li X, Zhu L Ren Fail. 2025; 47(1):2471568.

PMID: 40015727 PMC: 11869339. DOI: 10.1080/0886022X.2025.2471568.

Network meta-analysis of pharmacological treatment for antibody-mediated rejection after organ transplantation.

Sun J, Yu Y, Huang F, Zhang Q, Zhu L, He G Front Immunol. 2024; 15:1451907.

PMID: 39726594 PMC: 11669588. DOI: 10.3389/fimmu.2024.1451907.

Pharmacological Mechanisms of Cryptotanshinone: Recent Advances in Cardiovascular, Cancer, and Neurological Disease Applications.

Zheng Z, Ke L, Ye S, Shi P, Yao H Drug Des Devel Ther. 2024; 18:6031-6060.

PMID: 39703195 PMC: 11658958. DOI: 10.2147/DDDT.S494555.

Comprehensive Characterization of Anti-HLA and Non-HLA Antibodies in Patients on Kidney Transplant Waiting List and Evaluation of Their Impact on Alloimmunization Risk and Dialysis Treatment.

Mujic Franic A, Lilic M, Katalinic N, Glavas-Obrovac L Int J Mol Sci. 2024; 25(22).

PMID: 39596170 PMC: 11593988. DOI: 10.3390/ijms252212103.

Spatial Transcriptomic Signatures of Early Acute T Cell-mediated Rejection in Kidney Transplants.

Kang M, Kwon H, Song J, Jang Y, Yang S, Cha S Transplant Direct. 2024; 10(11):e1705.

PMID: 39399058 PMC: 11469874. DOI: 10.1097/TXD.0000000000001705.

References

de Vries D, van der Pol P, van Anken G, van Gijlswijk D, Damman J, Lindeman J . Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013; 95(6):816-20. DOI: 10.1097/TP.0b013e31827e31c9. View

Dempsey P, Allison M, Akkaraju S, Goodnow C, Fearon D . C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996; 271(5247):348-50. DOI: 10.1126/science.271.5247.348. View

Lalli P, Strainic M, Yang M, Lin F, Medof M, Heeger P . Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. 2008; 112(5):1759-66. PMC: 2518884. DOI: 10.1182/blood-2008-04-151068. View

Arumugam T, Shiels I, Strachan A, Abbenante G, Fairlie D, Taylor S . A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 2002; 63(1):134-42. DOI: 10.1046/j.1523-1755.2003.00737.x. View

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E . Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014; 124(11):1715-26. PMC: 4162105. DOI: 10.1182/blood-2014-02-558296. View

Vorup-Jensen T, Jensen R . Structural Immunology of Complement Receptors 3 and 4. Front Immunol. 2018; 9:2716. PMC: 6275225. DOI: 10.3389/fimmu.2018.02716. View

Schmitz R, Fitch Z, Schroder P, Choi A, Manook M, Yoon J . C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nat Commun. 2021; 12(1):5456. PMC: 8443599. DOI: 10.1038/s41467-021-25745-7. View

Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Aparecida Cavinato R . Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2010; 6(2):412-22. PMC: 3052234. DOI: 10.2215/CJN.04950610. View

Davis 3rd A, Mejia P, Lu F . Biological activities of C1 inhibitor. Mol Immunol. 2008; 45(16):4057-63. PMC: 2626406. DOI: 10.1016/j.molimm.2008.06.028. View

10.

Arbore G, West E, Rahman J, Le Friec G, Niyonzima N, Pirooznia M . Complement receptor CD46 co-stimulates optimal human CD8 T cell effector function via fatty acid metabolism. Nat Commun. 2018; 9(1):4186. PMC: 6180132. DOI: 10.1038/s41467-018-06706-z. View

11.

Huang E, Vo A, Choi J, Ammerman N, Lim K, Sethi S . Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2019; 15(1):109-116. PMC: 6946080. DOI: 10.2215/CJN.04840419. View

12.

Jane-Wit D, Manes T, Yi T, Qin L, Clark P, Kirkiles-Smith N . Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation. 2013; 128(23):2504-16. PMC: 3885874. DOI: 10.1161/CIRCULATIONAHA.113.002972. View

13.

de Clippel D, Baeten M, Torfs A, Emonds M, Feys H, Compernolle V . Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion. 2014; 54(12):3036-42. DOI: 10.1111/trf.12727. View

14.

Hengartner N, Fiedler J, Schrezenmeier H, Huber-Lang M, Brenner R . Crucial role of IL1beta and C3a in the in vitro-response of multipotent mesenchymal stromal cells to inflammatory mediators of polytrauma. PLoS One. 2015; 10(1):e0116772. PMC: 4285554. DOI: 10.1371/journal.pone.0116772. View

15.

Nauser C, Farrar C, Sacks S . Complement Recognition Pathways in Renal Transplantation. J Am Soc Nephrol. 2017; 28(9):2571-2578. PMC: 5576943. DOI: 10.1681/ASN.2017010079. View

16.

Tatapudi V, Montgomery R . Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads. Front Immunol. 2019; 10:2306. PMC: 6779821. DOI: 10.3389/fimmu.2019.02306. View

17.

Halloran P, Chang J, Famulski K, Hidalgo L, Salazar I, Merino Lopez M . Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol. 2014; 26(7):1711-20. PMC: 4483591. DOI: 10.1681/ASN.2014060588. View

18.

Li Q, Peng Q, Xing G, Li K, Wang N, Farrar C . Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol. 2010; 21(8):1344-53. PMC: 2938594. DOI: 10.1681/ASN.2009090977. View

19.

Merle N, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina L . Complement System Part II: Role in Immunity. Front Immunol. 2015; 6:257. PMC: 4443744. DOI: 10.3389/fimmu.2015.00257. View

20.

Farrar C, Zhou W, Lin T, Sacks S . Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006; 20(2):217-26. DOI: 10.1096/fj.05-4747com. View